James Amamoo (he/him/his)

Evidence Generation Manager
Novo Nordisk

Poster(s):

• (P118) REal-World Impact of Once-Weekly Injectable Semaglutide on GLycemic Control and Weight Outcomes Based on Highest Dose Received and Persistence With Treatment in Type 2 DiAbeTEs (RELATE – OW Injectable Semaglutide)
  Saturday, August 5, 2023

  11:00 AM – 1:00 PM CT

• (P119) REal-World Impact of Oral Semaglutide on GLycemic Control and Weight Outcomes Based on Highest Dose Received and Persistence With Treatment in Type 2 DiAbeTEs (RELATE – Oral Semaglutide)
  Saturday, August 5, 2023

  11:00 AM – 1:00 PM CT